Key indicators: single-crystal X-ray study; T = 113 K; mean (C-C) = 0.004 Å; R factor = 0.039; wR factor = 0.088; data-to-parameter ratio = 8.9.
In the title compound, C 18 H 21 N 3 O 6 , the dihedral angle between the two aromatic rings is 61.1 (1) . The crystal structure is stabilized by intermolecular O-HÁ Á ÁO hydrogen bonds. An intramolecular O-HÁ Á ÁO hydrogen bonds is also present.
Related literature
The title compound was obtained in an attempt to synthesise an intermediate for the antiretroviral drug raltegravir [systematic name N-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide], see: Belyk et al. 
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). (Steigbigel et al., 2008) . It received FDA approval in October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. When methyl 2-(2-(benzyloxycarbonyl)propan-2-yl) -5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylate was reacted with dimethyl sulfate catalyzed by magnesium methoxide in dimethyl sulfoxide (Belyk et al., 2006) , as we designed, in order to synthesize methyl 2-(2-(benzyloxycarbonyl)propan-2-yl) -5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate as the key intermediate of Raltegravir, two products appeared on thin layer chromatography. These products were separated through flash chromatography and the structures were conformed by nuclear magnetic resonance and X-ray analysis. The result showed that the title compound was the byproduct of the reaction.
The pyrimidinone ring is planar, as it is in a related compound (Fun et al., 2009) . This is in contrast with another related compound (Shang et al., 2007) , where the heterocyclic ring is twisted. In the title compound the dihedral angle between the two aromatic rings is 118.9 (1)°. The crystal structure is stabilized through intermolecular O-H···O hydrogen bonds; intramolecular O-H···O hydrogen bonds are also present.
To a slurry of methyl 2-(2-(benzyloxycarbonyl)propan-2-yl) -5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylate (1.5 g) and magnesium methoxide (2.1 g) in dimethyl sulfoxide(15 ml) at 70 °C, dimethyl sulfate (3.1 g) was added dropwise.
After addition, the mixture was heated at the same temperature for 8 h. To the reaction mixture was then added 40 ml 2 N HCl and then 100 ml water. Solid appeared when the mixture was stirred in an ice-water bath. The products were filtered and separated by flash chromatography. 50 mg of the title compound was dissolved in 30 ml methanol and the solution was kept at room temperature for 10 d; natural evaporation gave colorless single crystals of the title compound suitable for X-ray analysis. 
